Back to Journals » Journal of Blood Medicine » Volume 11

The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment

Authors Morotti A, Branca E, Guerrasio A

Received 23 September 2019

Accepted for publication 17 February 2020

Published 19 March 2020 Volume 2020:11 Pages 103—105

DOI https://doi.org/10.2147/JBM.S232109

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Martin H Bluth


Alessandro Morotti, Enrica Branca, Angelo Guerrasio

Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy

Correspondence: Alessandro Morotti
Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano 10043, Italy
Email alessandro.morotti@unito.it

Abstract: The reversal of low-molecular-weight heparin (LMWH) and the management of bleeding patients on LMWH remain highly challenging. Even if LMWH is very extensively administered in the prophylaxis and treatment of venous thrombosis, specific antidotes are lacking, and reversal strategies have very weak grade of evidences on clinical effectiveness. We here describe a reversal strategy with protamine and FVIIa in a patient presenting with hemorrhagic shock and cardiocirculatory arrest.

Keywords: LMWH bleeding, LMWH reversal, FVIIa, protamine, mantle lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]